The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for edaravone (Teva Pharma Australia Pty Ltd)
Active ingredients
edaravone
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
concentrated solution for injection
Indication
For the treatment of amyotrophic lateral sclerosis (ALS)
Therapeutic area
Neurology